May 18, 2012
Salix Pharmaceuticals Outlines Data Presentations At Digestive Disease Week 2012
May 07, 2012
Salix Pharmaceuticals Reports 1Q2012 Results
May 01, 2012
Salix Pharmaceuticals To Present At Three Investment Conferences In May
April 30, 2012
Salix Pharmaceuticals Announces Extension Of Crofelemer NDA Priority Review
April 25, 2012
Salix And Progenics Announce FDA Extension Of Relistor® sNDA Goal Date To July 27, 2012
April 23, 2012
Salix Pharmaceuticals Announces 1Q2012 Financial Results Conference Call And Webcast
March 16, 2012
Salix Pharmaceuticals Closes Sale Of Convertible Notes
March 13, 2012
Salix Pharmaceuticals Prices Convertible Notes Offering
March 12, 2012
Salix Pharmaceuticals Announces Proposed Convertible Notes Offering
February 28, 2012
Salix Pharmaceuticals To Present At Cowen Health Care Conference
February 27, 2012
Salix Pharmaceuticals Reports 4Q and FY2011 Results
February 21, 2012
Salix Pharmaceuticals Announces Initiation Of Target 3: A Phase 3 Study To Assess Repeat Treatment Efficacy And Safety Of Rifaximin 550Mg TID In Subjects With Irritable Bowel Syndrome With Diarrhea
February 21, 2012
Salix Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
February 13, 2012
Salix Pharmaceuticals Announces 4Q2011 and FY2011 Financial Results Conference Call and Webcast
February 07, 2012
Salix Pharmaceuticals Announces FDA Granting of Priority Review Designation for the Crofelemer NDA for Treatment of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy
January 04, 2012
Salix Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
December 20, 2011
Salix Pharmaceuticals Completes Acquisition of Oceana Therapeutics
December 20, 2011
Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation
December 14, 2011
Salix Pharmaceuticals Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea
November 29, 2011
Salix Pharmaceuticals to Present at Oppenheimer Healthcare Conference
November 16, 2011
FDA Advisory Committee Supports Proposed Clinical Trial Design to Evaluate Repeat Treatment Cycles of XIFAXAN® for Irritable Bowel Syndrome with Diarrhea
November 08, 2011
Salix Pharmaceuticals to Acquire Oceana Therapeutics
November 08, 2011
Salix Pharmaceuticals Reports 3Q2011 Results and Raises 2011 Guidance
November 04, 2011
Salix Pharmaceuticals Previews Data Slated for Presentation at 62nd Annual Meeting of The American Association for The Study of Liver Diseases
November 03, 2011
Salix Pharmaceuticals to Present at Two Investment Conferences in November